Healionics is addressing the critical need for improved means of vascular access for hemodialysis in patients with kidney failure. Our devices are based on our platform STAR® technology which provides substrate-independent, precision-engineered, 3D biomaterial scaffolds that enhance the biointegration and function of medical implants. Healionics holds 13 issued US and international patents with 12 pending.
Healionics, located in Seattle, has established strong connections and collaboration with the exceptional expertise developed from University of Washington’s key role in device and clinical innovations for treatment of kidney failure. These include the first blood access device which made long-term dialysis possible, early dialysis machines, and the first outpatient dialysis center. The area is also home to the Kidney Research Institute and Center for Dialysis Innovation.